Blogs

Matrix Biotek has joined the Barcelona Science Park ecosystem, further strengthening its presence in precision biotherapy monitoring across Europe. Serving as the European hub of the Matriks Biotek

We are seeking distribution and OEM partners across multiple international markets, including Australia, New Zealand, African countries, and South American countries, as well as other regions

We are pleased to announce the launch of our new SHIKARI® Enfortumab ELISA kits, developed to support precise and reliable monitoring of Enfortumab vedotin in clinical and research settings. These

This kit has been especially developed for the quantitative determination of antibodies to Semaglutide (Ozempic®) in serum and plasma.For more

This kit has been especially developed for the quantitative determination of Dupilumab in serum and plasma.For more information; https://matriksbiotek.com/products/320/shikari-q-dup-dupilumab-elisa 

Prof. Haluk Ataoglu MD, PhD, CEOMatriks Biotechnology Co.28 January 2025IntroductionBiological drugs—such as monoclonal antibodies—have transformed the treatment landscape for various autoimmune

Prof. Haluk Ataoglu MD, PhD, CEOMatriks Biotechnology Co. Abstract Biological therapies—including monoclonal antibodies, fusion proteins, and cytokines—are increasingly essential in the

EXAMPLE CASE: LAURA STEVENS Patient: Laura Stevens Forty-seven years old, high school teacher for over 20 years. "Three years ago, I was diagnosed with Non-Hodgkin's Lymphoma after experiencing

We are excited to announce our collaboration with Eagle Biosciences, Inc. , a highly experienced company in the marketing of Biological Drug Monitoring products in the United States. With 15 years of

This kit has been especially developed for the quantitative antibodies to Ocrelizumab in serum and plasma samples.For more

T-CAP NAB ASSAY™ ELISA KITS ARE DEVELOPED FOR TESTING ’FREE’ NEUTRALIZING ANTI-DRUG ANTIBODIESFOR MORE INFORMATION; https://matriksbiotek.com/shikari-t-cap-nab-assay-elisa-kits

Senior R&D and Production Director   Responsibilities:  Research and Development Team leader,  Writing project proposals for national and international grants, Recombinant protein

New Eculizumab ELISA kits are published. For more

New Adalimumab Specific ELISA kit is out! For more information;https://matriksbiotek.com/products/289/shikari-qs-ada

New Infliximab Specific ELISA kit is out! For more information;https://matriksbiotek.com/products/288/shikari-qs-inflixi

For more information please go Publications page!

To maintain leadership in its field, our vision is to produce the most innovative and highest quality products under the guidance of science and to offer them globally with full technical support and

New Risankizumab ELISA Kits are out! For more information,https://matriksbiotek.siteonizleme.com/shikari-products

New Pertuzumab ELISA Kits are out! For more information, https://matriksbiotek.siteonizleme.com/shikari-products

New Ixekizumab ELISA kits are out! For more information, https://matriksbiotek.siteonizleme.com/shikari-products